Abstract 3946
Background
Toll-like receptor (TLR) activation can enhance a range of antitumor immune responses via production of inflammatory cytokines and modulation of immune cells in the tumor microenvironment. GSK1795091 is a synthetic TLR4 agonist that showed immunomodulatory activity in preclinical cancer models (Gao et al. J Clin Oncol 2018) and successfully completed a safety, pharmacokinetic (PK) and pharmacodynamic (PD) study using IV administration in healthy volunteers. The current study will evaluate GSK1795091 with immunotherapies that have highly complementary mechanisms of action and supporting preclinical data (e.g. GSK3174998 [an OX40 agonist], GSK3359609 [an ICOS agonist], or pembrolizumab [a PD-1 inhibitor]) with the aim of generating greater antitumor activity than with monotherapy.
Trial design
This is a Phase I, open-label, non-randomized study in patients (≥18 years) with advanced solid tumors who have progressed on, or are ineligible for, standard therapy. In Part 1, up to 72 patients will be divided into 3 arms: GSK1795091 (50–250 ng IV; dose escalation) plus either GSK3174998 (24 mg IV), GSK3359609 (80 mg IV), or pembrolizumab (200 mg IV). GSK1795091 will be given weekly for 12 weeks; combination partners will be administered every 3 weeks (q3w) from Week 3 to allow a 2-week GSK1795091 monotherapy run-in period. After Week 12, GSK1795091 will be administered q3w, coinciding with the combination partner. Up to 6 participants per dose level may be enrolled into a PK/PD cohort for each combination. In Part 2, initial expansion cohorts of up to 15 patients with head and neck squamous cell carcinoma will be enrolled in each treatment arm at the dose(s) identified in Part 1. The primary objective is to evaluate the safety and tolerability of GSK1795091 combination therapy. Additional objectives include clinical activity, PK, PD and immunogenicity. Enrollment for the GSK1795091 + GSK3174998 arm began in March 2018; 12 patients have completed the first 2 dose cohorts. The remaining arms will commence enrollment in 1Q2019. Funded by GlaxoSmithKline.
Clinical trial identification
NCT03447314.
Editorial acknowledgement
Medical writing and editorial assistance was provided by Leigh O’Connor-Jones, PhD, of Fishawack Indicia Ltd and was funded by GSK.
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline.
Disclosure
A.R. Hansen: Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Boston Biomedical; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Research grant / Funding (institution): Karyopharm Therapeutics. J. Strauss: Shareholder / Stockholder / Stock options: Abbvie; Shareholder / Stockholder / Stock options: Abbott Laboratories; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb; Shareholder / Stockholder / Stock options: Intuitive Surgical; Shareholder / Stockholder / Stock options: Johnson and Johnson; Shareholder / Stockholder / Stock options: Merck; Advisory / Consultancy, Consulting agreement in 2017, no longer active: Tempus; Advisory / Consultancy, Member of advisory board: Dialectic Therapeutics. J. Chaves: Research grant / Funding (self), Research grant / Funding (institution): Immune Design; Research grant / Funding (self), Research grant / Funding (institution): Zymeworks; Research grant / Funding (self), Research grant / Funding (institution): Calithera; Research grant / Funding (self), Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (self), Research grant / Funding (institution): Merck; Research grant / Funding (self), Research grant / Funding (institution): EMD Serono; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Roche; Research grant / Funding (self), Research grant / Funding (institution): Genentech; Research grant / Funding (self), Research grant / Funding (institution): Array BioPharma; Research grant / Funding (self), Research grant / Funding (institution): Incyte; Research grant / Funding (self), Research grant / Funding (institution): Nektar; Research grant / Funding (self), Research grant / Funding (institution): Acerta Pharma; Research grant / Funding (self), Research grant / Funding (institution): Regeneron; Research grant / Funding (self), Research grant / Funding (institution): Halozyme; Research grant / Funding (self), Research grant / Funding (institution): Tesaro. S.A. Piha-Paul: Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): XuanZhu; Research grant / Funding (institution): Puma Biotechnology; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Merck Sharp & Dohme; Research grant / Funding (institution): Curis; Research grant / Funding (institution): Principa Biopharma; Research grant / Funding (institution): Helix BioPharma; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Five Prime Therapeutics; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): BlueLink; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Pieris Pharmaceuticals; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Samumed. H. Park: Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): BeiGene; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Gilead Sciences; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Macrogenics; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Millennium; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Puma Biotechnology; Research grant / Funding (institution): Regeneron. E. Garralda: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Principia Biopharma Inc.; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Genentech Inc; Research grant / Funding (institution): Loxo Oncology; Travel / Accommodation / Expenses: Menarini; Travel / Accommodation / Expenses: Glycotope; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck, Sharp & Dohme; Research grant / Funding (institution): Incyte Biosciences International; Research grant / Funding (institution): Pharma Mar, SA; Research grant / Funding (institution): Kura Oncology Inc; Research grant / Funding (institution): Macrogenics Inc; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: F. Hoffman/La Roche; Advisory / Consultancy: Ellipses Pharma; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Janssen Global Services; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Neomed Therapeutics Inc. C.J. Matheny: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. J. Carver: Full / Part-time employment: GlaxoSmithKline; Shareholder / Stockholder / Stock options: GlaxoSmithKline. A. Moore: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline. B.A. Hug: Shareholder / Stockholder / Stock options, Full / Part-time employment: GlaxoSmithKline.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract